The maker of the Oura Ring is expanding its push into the women's health sector by integrating its proprietary menopause survey with external healthcare providers. The company announced partnerships with ten health firms as part of a strategy to secure a larger foothold in a market estimated to be worth $25 billion.
The move positions Oura's wearable technology as a bridge between consumer health tracking and clinical care. By sharing survey data with partner organisations, the company aims to help women receive more targeted support for menopause-related symptoms, a field that has historically received limited attention from the medical establishment.
Oura's ring devices have gained popularity among consumers for tracking sleep, activity, and physiological metrics such as heart rate and body temperature. The company has been progressively building out features aimed at women's health, including cycle tracking and pregnancy insights. The new partnerships extend that work into menopause, where symptoms such as hot flushes, sleep disruption, and mood changes can now be monitored and reported in a structured format.
The ten partner companies span a range of healthcare services, though Oura has not disclosed the full commercial terms of the agreements. The integration is designed to allow clinicians and care providers to receive survey responses directly from the Oura platform, reducing the need for patients to repeat their history during consultations.
Industry analysts note that menopause care has become an increasingly competitive segment within digital health. Several startups and established medical firms have launched dedicated menopause clinics and telehealth services in recent years, responding to growing demand from patients who say their symptoms are often dismissed or undertreated.
Oura's approach differs from those offerings by leveraging its existing hardware base. The company already holds data on users' physiological patterns, which can provide context to the survey answers. For example, a woman reporting poor sleep on the survey may also have objective sleep-stage data from the ring, giving clinicians a more complete picture than a questionnaire alone.
The company frames the partnerships as a step toward more personalised care pathways. Rather than offering a one-size-fits-all menopause programme, Oura says the integrations will help direct women to appropriate services based on their individual symptom profiles and health history.
Regulatory considerations remain relevant. Health data is subject to strict privacy rules in many jurisdictions, and Oura has stated that its partnerships comply with applicable data protection standards. The company has not specified whether the survey data will be shared in identifiable form or aggregated before reaching partner organisations.
The expansion reflects a broader trend of consumer technology companies moving deeper into healthcare delivery. Wearable makers have increasingly sought to position their devices not merely as fitness trackers but as clinical-grade tools that can support diagnosis and treatment decisions. Oura's menopause initiative is among the most visible examples of a wearable company partnering directly with care providers rather than simply selling devices to individuals.
For the partners involved, the arrangement offers access to a demographic that is often underserved by traditional health systems. Menopause typically affects women in their late 40s and 50s, an age group with significant purchasing power and a growing willingness to seek out specialised care.